These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9892582)

  • 1. Good news for experimental concept but bad news for clinically effective therapy.
    Reimer KA; Califf RM
    Circulation; 1999 Jan; 99(2):198-200. PubMed ID: 9892582
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current therapy of coronary heart disease. Conservative measures].
    Stephan S
    Internist (Berl); 1998 Sep; 39(9):1001-2. PubMed ID: 9788131
    [No Abstract]   [Full Text] [Related]  

  • 3. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 4. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 5. [Induction of bradycardia by mibefradil in antihypertensive combination therapy].
    Wagner J; Ritz E
    Dtsch Med Wochenschr; 1998 Apr; 123(17):547. PubMed ID: 9601479
    [No Abstract]   [Full Text] [Related]  

  • 6. Rhabdomyolysis due to interaction of simvastatin with mibefradil.
    Schmassmann-Suhijar D; Bullingham R; Gasser R; Schmutz J; Haefeli WE
    Lancet; 1998 Jun; 351(9120):1929-30. PubMed ID: 9654265
    [No Abstract]   [Full Text] [Related]  

  • 7. Case report: rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin.
    Wombolt DG; Jackson A; Punn R; Smith S; McCune TR; Williams PB
    J Clin Pharmacol; 1999 Mar; 39(3):310-2. PubMed ID: 10073331
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
    Alpert JS
    Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
    [No Abstract]   [Full Text] [Related]  

  • 9. [Progress in new cardiovascular treatment. Background discussion and interview in the Basel Roche Research Center].
    Keil U
    Fortschr Med; 1996 Feb; 114(4):39-40. PubMed ID: 8852686
    [No Abstract]   [Full Text] [Related]  

  • 10. Serious interaction between mibefradil and tacrolimus.
    Krähenbühl S; Menafoglio A; Giostra E; Gallino A
    Transplantation; 1998 Oct; 66(8):1113-5. PubMed ID: 9808502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
    Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
    Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mibefradil and an effective formulary system.
    Vermeulen LC; Dunham DB
    Am J Health Syst Pharm; 1998 Sep; 55(18):1934-5. PubMed ID: 9784776
    [No Abstract]   [Full Text] [Related]  

  • 15. Comment: mibefradil, a new class of calcium-channel antagonists.
    Otterman S
    Ann Pharmacother; 1998 Dec; 32(12):1372. PubMed ID: 9876826
    [No Abstract]   [Full Text] [Related]  

  • 16. The withdrawal of mibefradil (Posicor).
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998; 17(2-3):59-60. PubMed ID: 9838964
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mibefradil (Posicor) induced sinus arrest.
    Sanders P; Walker J; Craig RJ; Hii JT; Steele PM
    Aust N Z J Med; 1998 Dec; 28(6):836-7. PubMed ID: 9972419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.